MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Maravai LifeSciences Holdings DSO Ratio 2011-2026 | MRVI
Annual DSO Ratio Maravai LifeSciences Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 | 52.9 | 26.8 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 122 | 26.8 | 67.3 |
Quarterly DSO Ratio Maravai LifeSciences Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.3 | 54.6 | 44.6 | 49.5 | 58.5 | 64.6 | 69.7 | 113 | - | - | 22.6 | 44.4 | - | 33.3 | 43 | 53.2 | - | 53 | 99.2 | 45.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 | 22.6 | 56.5 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akebia Therapeutics
AKBA
|
62.9 | $ 1.35 | -2.17 % | $ 347 M |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
58.1 | $ 330.71 | 3.72 % | $ 43.3 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.47 | 3.89 % | $ 306 M | USA |
 |
Amgen
AMGN
|
81.2 | $ 346.45 | -0.43 % | $ 186 B | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 12.37 | -0.92 % | $ 3.88 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 15.0 | 1.32 % | $ 220 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
114 | $ 76.34 | 2.87 % | $ 1.47 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.92 | -1.11 % | $ 5.02 M | China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.15 | 0.48 % | $ 444 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.43 | 4.98 % | $ 231 M |  Israel |
 |
Ardelyx
ARDX
|
58 | $ 6.08 | 2.27 % | $ 1.47 B | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
4.66 | $ 11.11 | 2.4 % | $ 788 M | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.57 | 0.88 % | $ 8.24 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Assembly Biosciences
ASMB
|
25.1 | $ 30.01 | 3.43 % | $ 336 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Atossa Therapeutics
ATOS
|
207 | $ 5.21 | -2.89 % | $ 44.9 M | USA |
 |
Atara Biotherapeutics
ATRA
|
4.13 | $ 5.03 | 0.7 % | $ 63.1 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
185 | $ 16.04 | 2.75 % | $ 2.16 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.42 | 0.35 % | $ 378 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |